Uptrend on the daily chart: above its 50- and 200-day averages · 50-day above the 200-day · SuperTrend up since Sep 22 · inside the Ichimoku cloud · RSI 60 · MACD above its signal · 2% below its 52-week high
None of the 29 investors followed here reported a position in GNGBY in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a GNGBY trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for GNGBY.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -7.3 | 3.3 | -12.3 | 1.0 | 2.2 | -0.8 | 22.3 | 3.1 | -3.7 | 3.0 | +7.5% | ||
| 2025 | 19.4 | 1.2 | 8.5 | -10.2 | -0.4 | 4.0 | -2.1 | 11.6 | -1.1 | 9.8 | -5.4 | 5.4 | +44.3% |
| 2024 | -2.3 | -9.2 | 1.9 | 5.4 | -16.2 | -5.0 | 15.5 | 6.6 | 3.3 | -18.3 | -10.4 | 4.3 | −26.3% |
| 2023 | 8.6 | -4.3 | 13.5 | 4.1 | -9.2 | -24.1 | 6.5 | -7.0 | 1.5 | 2.1 | 18.2 | 4.9 | +7.8% |
| 2022 | -10.7 | -1.5 | 3.8 | -27.8 | 0.9 | -20.4 | -3.9 | -16.8 | -7.8 | 18.3 | 14.7 | -10.9 | −52.8% |
| 2021 | 9.6 | -2.0 | 9.7 | 22.8 | 4.6 | 6.1 | 15.6 | -5.8 | -3.1 | 13.3 | -6.1 | 3.7 | +87.1% |
| 2020 | -8.3 | -1.4 | 13.7 | -0.5 | -4.0 | 1.8 | 31.4 | -8.6 | -1.8 | -11.2 | 9.8 | 9.9 | +26.3% |
| 2019 | 25.2 | 4.6 | -1.4 | 19.9 | -3.1 | 16.6 | -7.8 | -5.0 | 1.6 | 21.2 | 2.2 | 6.8 | +106.2% |
| 2018 | -5.9 | -8.1 | -8.8 | -17.8 | 2.5 | -6.2 | 18.9 | 11.0 | -3.0 | -15.4 | 5.2 | -12.5 | −38.0% |
| 2017 | 0.2 | 4.7 | 3.6 | 10.8 | 7.0 | -6.1 | -11.3 | 8.2 | 0.1 | 5.1 | -8.8 | -19.2 | −10.1% |
| 2016 | -15.8 | 1.8 | 2.6 | -8.4 | 1.1 | -3.6 | -1.4 | -3.9 | -0.6 | -15.4 | -6.8 | 5.9 | −38.4% |
| 2015 | 10.1 | 10.4 | -10.3 | -1.9 | 0.6 | -1.3 | 1.7 | -9.4 | 0.6 | 13.0 | 0.5 | 3.2 | +15.5% |
| 2014 | 0.9 | 4.1 | -21.7 | 4.3 | -12.4 | 2.1 | -7.3 | 8.3 | -4.7 | -7.9 | 0.2 | -2.2 | −33.8% |
| 2013 | -8.5 | -3.5 | 2.2 | -1.5 | -1.5 | 2.2 | 22.0 | -7.3 | 4.2 | -11.6 | -1.3 | 9.3 | +0.5% |
| 2012 | 0.0 | 5.5 | 3.7 | 5.1 | +14.9% |
No analyst coverage for this instrument.
Getinge AB (publ) provides products and solutions for operating rooms, intensive-care units, and sterilization departments in Sweden and internationally. The company operates through Acute Care Therapies, Life Science, and Surgical Workflows segments. It offers extracorporeal membrane oxygenation, mechanical ventilation, advanced patient monitoring, ICU infrastructure equipment, and drainage solutions. In addition, the company provides surgical perfusion, endoscopic vessel harvesting, intra-aortic balloon counterpulsation, vascular and cardiothoracic surgery equipment, peripheral stenting, OEM solutions, and beating heart surgery equipment; and operating room equipment, anesthesia, advanced patient monitoring, and operating room integration solutions. Further, it offers pre-cleaning, cleaning and disinfection, sterilization, consumables, endoscope reprocessing, and sterile supply management solutions; connected medical devices, and patient flow management; and low temperature sterilization, biocontainment in vaccine production, terminal sterilization, sterile isolation technology, cleaning and sterilization, aseptic transfer, and large-scale cultivation. Additionally, the company provides bioreactor preparation solution, bioprocess development and optimization, labware cleaning and sterilization, biocontainment, and vivarium. It offers its products through a network of sales companies, as well as through agents and distributors in the Americas, Europe, the Middle East, Africa, and the Asia and Pacific. Getinge AB (publ) was founded in 1904 and is headquartered in Gothenburg, Sweden.